Precision medicine has helped identify several tumor molecular aberrations to be treated
with targeted therapies. These therapies showed substantial improvement in efficacy without …

In recent years, we have seen the development and approval for clinical use of an
increasing number of therapeutic agents against actionable oncogenic drivers in metastatic …

Mesenchymal-epithelial transition (MET) receptor tyrosine kinase is overexpressed,
amplified, or mutated in 1–20% of NSCLC. MET dysregulation is associated with a poor …

Genetic alterations in mesenchymal-epithelial transition (MET) are commonly found in solid
tumors, especially in non-small cell lung cancer (NSCLC). However, agents targeting MET …

Abstract Aberrant c-MET (Mesenchymal–Epithelial Transition) signaling contributes to
cancer cell development, proliferation, and metastases of non-small cell lung cancer …

Capmatinib and tepotinib received US Food and Drug Administration (FDA) approval for
mesenchymal-epithelial transition (MET) exon 14 (METex14) skipping alteration in 2020 and …

The mesenchymal-epithelial transition (MET) receptor tyrosine kinase binds the hepatocyte
growth factor to activate downstream cell signaling pathways involved in cell proliferation …

Abnormal activation of mesenchymal epithelial transition (MET) receptor tyrosine kinase is
associated with oncogenesis. Various underlying mechanisms, including alteration …

Simple Summary In this narrative review, we discuss the development of capmatinib, a
reversible MET tyrosine kinase inhibitor that received approval for advanced non-small cell …

The emergence of molecular medicine has led to the increased development and rapid
approval of small molecule inhibitors which have caused a dramatic shift in the therapeutic …